16
upregulation of phosphoinositide 3-kinase prevents sunitinib-induced cardiotoxicity in vitro and in vivo. (2019).[10.1007_s00204-019-02448-z].pdf
upregulation of phosphoinositide 3-kinase prevents sunitinib-induced cardiotoxicity in vitro and in vivo. (2019).[10.1007_s00204-019-02448-z]
13
the alternative 2_1 schedule of sunitinib is superior to the traditional 4_2 schedule in patients with metastatic renal cell carcinoma_ a meta-anal.pdf
the alternative 2_1 schedule of sunitinib is superior to the traditional 4_2 schedule in patients with metastatic renal cell carcinoma_ a meta-anal
22
Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer A Phase III, Randomized, Open-Label Trial.pdf
Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer A Phase III, Randomized, Open-Label Trial
22
肾切除手术Sunitinib 50 mgday (Schedule 42).ppt
肾切除手术Sunitinib 50 mgday (Schedule 42)
20
Quantitation of unbound sunitinib and its metabolite N-desethyl sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry (LCMSM...pdf
Quantitation of unbound sunitinib and its metabolite N-desethyl sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid chromatography–tandem mass spectrometry (LCMSMS) application to a pharmacokinetic study
32
Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer.pdf
Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancerSynergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancerSynergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer
20
Pharmacodynamic Study Using FLT PETCT in Patients with Renal Cell Cancer and Other Solid Malignancies Treated with Sunitinib Malate.pdf
Pharmacodynamic Study Using FLT PETCT in Patients with Renal Cell Cancer and Other Solid Malignancies Treated with Sunitinib Malate
29
Synergistic survival a new phenomenon connected to adverse events of first-line sunitinib treatment in advanced renal cell carcinoma.pdf
Synergistic survival a new phenomenon connected to adverse events of first-line sunitinib treatment in advanced renal cell carcinoma

向豆丁求助:有没有sunitinib?

如要投诉违规内容,请联系我们按需举报;如要提出意见建议,请到社区论坛发帖反馈。